Selective manipulation of these pathways can achieve long-term persistence and anti-tumor activity of CAR-T cells, which is attributed to the application of gene editing technology in CAR structure design, which is expected to provide further space for mutation or modification of CD28 structural domains. Here, CD28 is linked to neoplasm.